VA
WHWK

Verdad Advisers’s Whitehawk Therapeutics WHWK Stock Holding History

Verdad Advisers’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
301,483
+185,999
+161% +$774K 1.32% 13
2026
Q1 		$398K Buy
+115,484
New +$362K 0.45% 80

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verdad Advisers's WHWK Position: Q2 2026 in Review

Verdad Advisers increased its Whitehawk Therapeutics (WHWK) stake by 161% in Q2 2026, buying an estimated $774K and bringing the position to 301,483 shares worth $1.38M. The position accounts for 1.32% of the portfolio, ranked #13.

Verdad Advisers first reported a position in WHWK in Q1 2026 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Verdad Advisers held 301,483 shares of Whitehawk Therapeutics worth $1.38M as of Q2 2026.
  • Verdad Advisers bought 185,999 Whitehawk Therapeutics shares in Q2 2026, an estimated $774K.
  • Whitehawk Therapeutics made up 1.32% of Verdad Advisers's portfolio in Q2 2026, its #13 holding.
  • Verdad Advisers first reported a position in Whitehawk Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.